Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

is Phase 1 trial, the Company anticipates launching a Phase 2 clinical trial with new HspE7 in patients with cervical intraepithelial neoplasia (CIN). The Company is also in discussions with clinical investigators regarding the design and implementation of a second Phase 2 trial with new HspE7 in patients that are HIV-positive with low-grade CIN.

Affiliations and investigators in this trial currently include the Montefiore Medical Center; William D. Kolton, M.D. of San Diego, California; Linda Roman, M.D. of the University of Southern California (USC); Michael L. Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T. Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research in Pleasant Grove, Utah.

About HspE7 + Poly-ICLC:

The Company's lead candidate, HspE7 + Poly-ICLC, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 + Poly-ICLC contains the novel CoVal(TM) fusion protein, HspE7, that is co-administered with the adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist adjuvant. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 + Poly-ICLC for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nven
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PLAINS, N.Y. , July 23, 2014 /PRNewswire-USNewswire/ ... approval of idelalisib to treat patients with relapsed ... small lymphocytic lymphoma (SLL) is a significant advance ... Idelalisib, which goes by the trade name ... a protein that is highly expressed in many ...
(Date:7/23/2014)... July 23, 2014  Varian Medical Systems (NYSE: ... $1.02 per diluted share in the third quarter of ... about $0.06 per diluted share due to an approximately ... Varian,s existing equity investment in Augmenix, a privately-held company ... totaled $748 million for the third quarter of fiscal ...
(Date:7/23/2014)... Conn. , July 23, 2014 UBM ... – a new online community and information resource ... better manage and treat their patients with neurological ... coupled with an aging population, necessitates greater access to ... disorders.  Key statistics on neurological conditions include: ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3
... Rochester Medical Implants ( http://www.rmi.us.com ), a contract manufacturer ... it has relocated corporate offices and manufacturing operations to ... the location change, the company will change its name ... The new facility is a modern 33,000-square ...
... Calif., Oct. 17, 2011 ChemoCentryx, Inc., today ... trial for CCX168, an orally-administered small molecule for ... (AAV), a disease which can lead to renal ... receptor (C5aR), a potent pro-inflammatory mediator that is ...
Cached Medicine Technology:Rochester Medical Implants Relocates to New Facility in Noblesville, IN 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 3ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 4
(Date:7/23/2014)... Lake Worth, FL (PRWEB) July 23, 2014 ... will take place Aug. 10-16, Millennium Treatment Group is ... Substance abuse has existed in society ever since man ... make wine. Substance abuse treatment has existed since shortly ... of recognizing a problem and then developing a way ...
(Date:7/23/2014)... July 23, 2014 A new study ... power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive ... throughout a woman’s body, Bernstein Liebhard LLP reports. The ... Journal of the American Medical Association, looked at 36,000 ... at 500 U.S. hospitals from 2006 to 2012. Ninety-nine ...
(Date:7/23/2014)... Alan Mozes HealthDay Reporter ... servicemen are more likely to have been exposed to some ... new survey suggests. The finding seems to apply solely ... that the finding could be a cause for concern, given ... and/or sexual abuse among the civilian population has been linked ...
(Date:7/23/2014)... YORK, NY, July 24, 2014) If past experience ... York State are about to get a lot more ... laws already on the books allowing NPs to provide ... to patient care and better relationships with physicians and ... a study from Columbia University School of Nursing, published ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3Health News:New York law offers nurses more recognition, responsibility 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3
... has earmarked $74 million to combat the bird flu threat ... was to announce the funding in Busan, Korea, where he ... ,International agencies, like the World Health Organization (WHO), would ... would go on a simulation exercise run by APEC to ...
... to the World Health Organization (WHO) experts, concerted ... complete eradication of the five neglected tropical diseases ... // years. , WHO has identified five ... leishmaniasis (kala azar), soil transmitted helminths (STH) and ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... by the Italian phrase 'malaria' — or 'bad air' — ... days, scientists know malaria is spread by mosquitos. // And ... the spread of a disease that kills 1 million people ... the situation is bad. The number of deaths are rising, ...
... hospital will begin performing open-heart surgeries on patients in ... new unit equipped with the // latest equipment including ... light, automatic operation bed and latest x-ray machines for ... superintendent, IGMC., ,The new unit will be launched ...
... movie may induce enough stress to interfere with your ... you sit down to watch a violent or // ... ability. ,David Beversdorf, a neurologist at the State ... and asked them to combine movie viewing with problem-solving ...
Cached Medicine News:Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Malaria Vaccine May Be 10 Years Away 2Health News:Malaria Vaccine May Be 10 Years Away 3
... CO2 laser system used in neurophysiology for studying ... the amplitude and/or the duration of the stimulus ... the laser emission in an ongoing manner by ... this laser include the high repeatability of the ...
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
Smart Chill is a compact cooling system that provides intense localised skin cooling through a comfortable contact handpiece....
... Smart 1064 DW with the capability of ... nm) offering increased coagulative and ablative capacities.Smart 1064 ... between two different wavelengths: ordinary 1064 nm (with ... 1320 nm (with powers among 2 and 25 ...
Medicine Products: